Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors | Zendy

Adrian Lee | Zendy; David L. Chan | Zendy; Matthew H. Wong | Zendy; Bob T. Li | Zendy; S. P. Lumba | Zendy; Stephen Clarke | Zendy; Jaswinder S. Samra | Zendy; Nick Pavlakis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors

Author(s) -

Adrian Lee,

David L. Chan,

Matthew H. Wong,

Bob T. Li,

S. P. Lumba,

Stephen Clarke,

Jaswinder S. Samra,

Nick Pavlakis

Publication year - 2016

Publication title -

neuroendocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.493

H-Index - 101

eISSN - 1423-0194

pISSN - 0028-3835

DOI - 10.1159/000446115

Subject(s) - medicine , neuroendocrine tumors , randomized controlled trial , everolimus , progression free survival , oncology , targeted therapy , cancer , overall survival

Targeted therapies [interferon (IFN), vascular endothelial growth factor (VEGF) inhibitors, and somatostatin analogs (SSA)] have become an integral part of the neuroendocrine tumor (NET) treatment paradigm. We systematically reviewed the available literature to assess the overall beneficial and negative effects of targeted therapy on progression-free survival (PFS), overall survival (OS), response rate (RR), and toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research